Literature DB >> 31758497

Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy.

Muhammad Asim Farooq1, Md Aquib1, Daulat Haleem Khan2, Zahid Hussain3, Anam Ahsan4, Mirza Muhammad Faran Ashraf Baig5, Dickson Pius Wande1, Muhammad Masood Ahmad6, Hafiz Muhammad Ahsan7, Jiang Jiajie1, Bo Wang8.   

Abstract

BACKGROUND: Disulfiram (DSF) has a long history of being used as a first-line promising therapy for treatment of alcoholism in human. Besides its prominence in the treatment of alcoholism, extensive investigations have been carried out to explore other biomedical and pharmacological effects of DSF. Amongst other biomedical implications, plenty researches have shown evidence of promising anticancer efficacy of this agent for treatment of wide range of cancers such as breast cancer, liver cancer and lung carcinoma.
METHODS: Electronic databases, including Google scholar, PubMed and Web of science were searched with the keywords disulfiram, nanoparticles, cancer, drug delivery systems. RESULT: Despite its excellent anticancer efficacy, the pharmaceutical significance and clinical applicability of DSF are hampered due to poor stability, low solubility, short plasma half-life, rapid metabolism, and early clearance from systemic circulation. Various attempts have been made to eradicate these issues. Nanotechnology based interventions have gained remarkable recognition in improving pharmacokinetic and pharmacodynamic profile of DSF by improving its stability and avoiding its degradation.
CONCLUSION: The aim of the present review is to critically analyse all recent developments in designing various nanotechnology-based delivery systems, to ponder their relevance in improving stability, pharmacokinetic and pharmacodynamic profile, and achieving target-specific delivery of this agent to cancer cells to effectively eradicate cancer and abolish its metastasis. Nanotechnology is a novel approach for overcoming such obstacles faced presently, the results obtained so far using different novel drug delivery systems seem to be very promising to increase the stability and half-life of DSF. Graphical abstract Nanocrrier mediated drug delivery systems for disulfiram.

Entities:  

Keywords:  Cancer; Disulfiram; Drug delivery systems; Nanotechnology; Polymeric nanoparticles

Mesh:

Substances:

Year:  2019        PMID: 31758497      PMCID: PMC6895293          DOI: 10.1007/s40199-019-00308-w

Source DB:  PubMed          Journal:  Daru        ISSN: 1560-8115            Impact factor:   3.117


  60 in total

Review 1.  Drug repositioning: identifying and developing new uses for existing drugs.

Authors:  Ted T Ashburn; Karl B Thor
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

2.  Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram).

Authors:  Boris Cvek
Journal:  Drug Discov Today       Date:  2011-12-16       Impact factor: 7.851

3.  Studies on the metabolic activation of disulfiram in rat. Evidence for electrophilic S-oxygenated metabolites as inhibitors of aldehyde dehydrogenase and precursors of urinary N-acetylcysteine conjugates.

Authors:  P Hu; L Jin; T A Baillie
Journal:  J Pharmacol Exp Ther       Date:  1997-05       Impact factor: 4.030

4.  Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.

Authors:  Jianqing Lin; Michael C Haffner; Yonggang Zhang; Byron H Lee; W Nathaniel Brennen; Justin Britton; Sushant K Kachhap; Joong Sup Shim; Jun O Liu; William G Nelson; Srinivasan Yegnasubramanian; Michael A Carducci
Journal:  Prostate       Date:  2010-08-31       Impact factor: 4.104

5.  Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer.

Authors:  Mohammad Najlah; Zahima Ahmed; Mohammed Iqbal; Zhipeng Wang; Patrica Tawari; Weiguang Wang; Christopher McConville
Journal:  Eur J Pharm Biopharm       Date:  2016-11-30       Impact factor: 5.571

6.  Inhibitory effect of Disulfiram/copper complex on non-small cell lung cancer cells.

Authors:  Lincan Duan; Hongmei Shen; Guangqiang Zhao; Runxiang Yang; Xinyi Cai; Lijuan Zhang; Congguo Jin; Yunchao Huang
Journal:  Biochem Biophys Res Commun       Date:  2014-03-19       Impact factor: 3.575

7.  A Copper-Mediated Disulfiram-Loaded pH-Triggered PEG-Shedding TAT Peptide-Modified Lipid Nanocapsules for Use in Tumor Therapy.

Authors:  Ling Zhang; Bin Tian; Yi Li; Tian Lei; Jia Meng; Liu Yang; Yan Zhang; Fen Chen; Haotian Zhang; Hui Xu; Yu Zhang; Xing Tang
Journal:  ACS Appl Mater Interfaces       Date:  2015-11-04       Impact factor: 9.229

8.  The inhibitory effect of disulfiram encapsulated PLGA NPs on tumor growth: Different administration routes.

Authors:  Hamidreza Fasehee; Ghazaleh Zarrinrad; Seyed Mohammad Tavangar; Seyed Hamidollah Ghaffari; Shahab Faghihi
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2016-03-09       Impact factor: 7.328

9.  pH-triggered surface charge-switchable polymer micelles for the co-delivery of paclitaxel/disulfiram and overcoming multidrug resistance in cancer.

Authors:  Qiang Huo; Jianhua Zhu; Yimin Niu; Huihui Shi; Yaxiang Gong; Yang Li; Huihui Song; Yang Liu
Journal:  Int J Nanomedicine       Date:  2017-12-04

10.  Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells.

Authors:  Sang Kyum Kim; Honsoul Kim; Da-Hye Lee; Tae-shin Kim; Tackhoon Kim; Chaeuk Chung; Gou Young Koh; Hoguen Kim; Dae-Sik Lim
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

View more
  2 in total

1.  Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study.

Authors:  Lisa Zirjacks; Nicolai Stransky; Lukas Klumpp; Lukas Prause; Franziska Eckert; Daniel Zips; Sabine Schleicher; Rupert Handgretinger; Stephan M Huber; Katrin Ganser
Journal:  Biomolecules       Date:  2021-10-21

2.  Aldehyde Dehydrogenase 2 Family Member (ALDH2) Is a Therapeutic Index for Oxaliplatin Response on Colorectal Cancer Therapy with Dysfunction p53.

Authors:  Wei-Lin Wang; Uyanga Batzorig; Chin-Sheng Hung; Po-Li Wei; Chien-Yu Huang; Yu-Jia Chang
Journal:  Biomed Res Int       Date:  2022-02-07       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.